Comparison of PD-L1 assays in head and neck carcinoma

IF 3.6 3区医学 Q1 PATHOLOGY

Pathology Pub Date : 2024-08-22 DOI:10.1016/j.pathol.2024.06.006

Ji-Seon Jeong, Uiree Jo, Gyuheon Choi, Halim Song, Kyung-Ja Cho, Joon Seon Song

{"title":"Comparison of PD-L1 assays in head and neck carcinoma","authors":"Ji-Seon Jeong, Uiree Jo, Gyuheon Choi, Halim Song, Kyung-Ja Cho, Joon Seon Song","doi":"10.1016/j.pathol.2024.06.006","DOIUrl":null,"url":null,"abstract":"Programmed cell death-ligand 1 (PD-L1) expression is a predictive biomarker for immune checkpoint inhibitor in head and neck squamous cell carcinoma. Given the range of antibodies and platforms for PD-L1 testing, it is essential to understand the performance of different staining and scoring methods. PD-L1 expression in 156 head and neck mucosal squamous cell carcinoma (HNmSCC) cases at Asan Medical Center was assessed using 106 TMA cores and 50 whole slides. Three standardised PD-L1 assays (22C3 pharmDx, SP263, and 28-8 pharmDx) and one laboratory-developed test (22C3 LDT) were evaluated: the combined positive score (CPS) with ≥1, ≥20, and ≥50 cut-offs, and the tumour positive score (TPS) with ≥1%, ≥20%, ≥50% cut-offs. Concordance on a continuous scale among the assays was good to excellent for CPS [intraclass correlation coefficient (ICC) range 0.73–0.94] and TPS (ICC range 0.70–0.94) and in both TMA and whole slides cohorts. Stratification by variable cut-offs demonstrated moderate to good agreement among most assays, as analysed by Gwet's AC1. PD-L1 expression was significantly correlated with tumour location using the 22C3 pharmDx assay (CPS, =0.014; TPS, =0.033). Notable concordance was found among PD-L1 assays, suggesting their potential interchangeability in HNmSCC.","PeriodicalId":19915,"journal":{"name":"Pathology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.pathol.2024.06.006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Programmed cell death-ligand 1 (PD-L1) expression is a predictive biomarker for immune checkpoint inhibitor in head and neck squamous cell carcinoma. Given the range of antibodies and platforms for PD-L1 testing, it is essential to understand the performance of different staining and scoring methods. PD-L1 expression in 156 head and neck mucosal squamous cell carcinoma (HNmSCC) cases at Asan Medical Center was assessed using 106 TMA cores and 50 whole slides. Three standardised PD-L1 assays (22C3 pharmDx, SP263, and 28-8 pharmDx) and one laboratory-developed test (22C3 LDT) were evaluated: the combined positive score (CPS) with ≥1, ≥20, and ≥50 cut-offs, and the tumour positive score (TPS) with ≥1%, ≥20%, ≥50% cut-offs. Concordance on a continuous scale among the assays was good to excellent for CPS [intraclass correlation coefficient (ICC) range 0.73–0.94] and TPS (ICC range 0.70–0.94) and in both TMA and whole slides cohorts. Stratification by variable cut-offs demonstrated moderate to good agreement among most assays, as analysed by Gwet's AC1. PD-L1 expression was significantly correlated with tumour location using the 22C3 pharmDx assay (CPS, =0.014; TPS, =0.033). Notable concordance was found among PD-L1 assays, suggesting their potential interchangeability in HNmSCC.

查看原文本刊更多论文

头颈癌中 PD-L1 检测方法的比较

程序性细胞死亡配体1（PD-L1）表达是头颈部鳞状细胞癌免疫检查点抑制剂的预测性生物标记物。鉴于用于检测 PD-L1 的抗体和平台种类繁多，了解不同染色和评分方法的性能至关重要。我们使用106个TMA核芯和50张完整切片评估了牙山医疗中心156例头颈部粘膜鳞状细胞癌（HNmSCC）的PD-L1表达情况。评估了三种标准化的 PD-L1 检测方法（22C3 pharmDx、SP263 和 28-8 pharmDx）和一种实验室开发的检测方法（22C3 LDT）：≥1、≥20 和≥50 分界点的联合阳性评分 (CPS)，以及≥1%、≥20% 和≥50% 分界点的肿瘤阳性评分 (TPS)。CPS[类内相关系数（ICC）范围为0.73-0.94]和TPS（ICC范围为0.70-0.94）以及TMA和全切片队列中的检测方法的连续一致性从良好到极佳。根据 Gwet's AC1 分析，按变量临界值进行的分层显示，大多数检测方法之间的一致性为中等至良好。使用 22C3 pharmDx 检测法，PD-L1 表达与肿瘤位置有明显相关性（CPS，=0.014；TPS，=0.033）。PD-L1 检测方法之间存在明显的一致性，这表明它们在 HNmSCC 中具有潜在的互换性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pathology 医学-病理学

CiteScore

6.50

自引率

2.20%

发文量

459

审稿时长

54 days

期刊介绍： Published by Elsevier from 2016 Pathology is the official journal of the Royal College of Pathologists of Australasia (RCPA). It is committed to publishing peer-reviewed, original articles related to the science of pathology in its broadest sense, including anatomical pathology, chemical pathology and biochemistry, cytopathology, experimental pathology, forensic pathology and morbid anatomy, genetics, haematology, immunology and immunopathology, microbiology and molecular pathology.